Volume 5.21 | May 30

Cord Blood News 5.21 May 30, 2013
     In this issue: Publications | Reviews | Industry News | Policy News | Events | Jobs
Cell Therapy News on Facebook  Cord Blood News on Twitter
TOP STORY
Role of HIF-1α-Activated Epac1 on Hematopoietic Stem Cell-Mediated Neuroplasticity in Stroke Model
Researchers report that hypoxia upregulated exchange protein activated by cAMP-1 (Epac1) through HIF-1α induction in the CD34-immunosorted human umbilical cord blood hematopoietic stem cells (hUCB34). Importantly, implantation of hUCB34 subjected to hypoxia-preconditioning improved stroke outcome, more than did implantation of untreated hUCB34, in rodents subjected to cerebral ischemia, and this required Epac1-to-matrix metalloprotease signaling. [Neurobiol Dis] Abstract

Happy Birthday mTeSR™1! 5 years of Groundbreaking Research and Counting
PUBLICATIONS (Ranked by impact factor of the journal)

Significant Improvement in Survival after Allogeneic Hematopoietic Cell Transplantation during a Period of Significantly Increased Use, Older Recipient Age, and Use of Unrelated Donors
Over the past four decades, allogeneic hematopoietic cell transplantation has evolved as a curative modality for patients with hematologic diseases. Researchers described changes in use, technique, and survival in a population-based cohort. [J Clin Oncol] Abstract | Press Release

Immunological Properties of Extraembryonic Human Mesenchymal Stromal Cells Derived from Gestational Tissue
Investigators compared the phenotype, proliferation rate, migration, immunogenicity, and immunomodulatory capabilities of human mesenchymal stromal cells derived from umbilical cord lining, umbilical cord blood, placenta, and Wharton’s jelly. [Stem Cells Dev] Abstract

Conversion of Human Umbilical Cord Mesenchymal Stem Cells in Wharton’s Jelly to Dopamine Neurons Mediated by the Lmx1a and Neurturin In Vitro: Potential Therapeutic Application for Parkinson’s Disease in a Rhesus Monkey Model
Scientists investigated a novel neuronal differentiation strategy in vitro with Lmx1α and neurturin (NTN). They transferred these two genes to hUC-MSCs by recombinant adenovirus combined with Lmx1α regulatory factor and other inductor to improve the efficiency of inducing. Then those induced cells were implanted into the striatum and substantia nigra of MPTP lesioned hemi-parkinsonian rhesus monkeys. [PLoS One]
Full Article

Efficient Generation of Integration-Free iPS Cells from Human Adult Peripheral Blood Using BCL-XL Together with Yamanaka Factors
Researchers successfully generated integration-free induced pluripotent stem cells (iPS) from cord blood CD34+ cells with improved oriP/EBNA1-based episomal vectors (EV) using a strong spleen focus forming virus long terminal repeat promoter. They showed that Yamanaka factors (OCT4, SOX2, MYC, and KLF4)-expressing EV can also reprogram adult peripheral blood mononuclear cells into pluripotency, yet at a very low efficiency. They found that inclusion of BCL-XL increases the reprogramming efficiency by approximately ten-fold. [PLoS One] Full Article

Metabolic Glycoengineering of Mesenchymal Stromal Cells with N-Propanoylmannosamine
Scientists showed by mass spectrometric analysis of cell surface N-glycans that about half of N-acetylneuraminic acid was replaced by N-propanoylneuraminic acid in the N-glycans of human umbilical cord blood derived mesenchymal stromal cells supplemented with N-propanoylmannosamine. [Glycobiology] Abstract

Neutrophilic Myeloid-Derived Suppressor Cells in Cord Blood Modulate Innate and Adaptive Immune Responses
Investigators demonstrated that a distinct myeloid-derived suppressor cell subset with a neutrophilic / granulocytic phenotype is highly increased in cord blood compared to peripheral blood of children and adults. [Clin Exp Immunol] Abstract | Full Article

Optimizing Donor Selection for Public Cord Blood Banking: Influence of Maternal, Infant, and Collection Characteristics on Cord Blood Unit Quality
Characteristics of 5267 cord blood units (CBUs) were retrospectively analyzed. High-quality CBUs were defined as those with higher postprocessing total nucleated cell count with CD34+ and colony-forming units (CFUs) in the upper quartile. Factors associated with higher CD34+ or CFU content included a shorter interval from collection to processing, younger gestational age, Caucasian race, higher birthweight, and larger collection volumes. [Transfusion] Abstract

Identification of Endothelial Cell Surface Antigens Encoded by Genes Other than HLA. A Combined Immunoprecipitation and Proteomic Approach for the Identification of Antigens Recognized by Antibodies against Endothelial Cells in Transplant Recipients
Researchers attempted to characterize endothelial cell surface antigens to which antibodies were produced during graft rejection. They used a panel of endothelial cells from umbilical cord veins and found that antibodies with a polymorphic pattern in the panel appeared to correlate with transplant failure of kidney allografts and with the development of transplant-related coronary artery disease in heart transplant recipients. [Hum Immunol] Abstract

Register for new mouse/rat HSC CFU training course.

REVIEWS
Stem Cells in Retinal Regeneration: Past, Present and Future
Stem cell therapy for retinal disease is under way, and several clinical trials are currently recruiting. These trials use human embryonic, fetal and umbilical cord tissue-derived stem cells and bone marrow-derived stem cells to treat visual disorders such as age-related macular degeneration, Stargardt’s disease and retinitis pigmentosa. The authors review these various stem cell-based approaches for treating retinal diseases and discuss future directions and challenges for the field. [Development] Full Article

Visit our reviews page to see a complete list of reviews in the cord blood research field.

MSC 2013 - Adult Stem Cell Therapy & Regenerative Medicine
INDUSTRY NEWS

Stem Cell Agency Awards More than $42 Million in New Research and Leadership Funding
California’s position as a global leader in stem cell research has been strengthened by the awarding of $36 million in funds to attract six world-class scientists to the state, and more than $6 million to create a partnership with Sangamo BioSciences to develop a therapy for beta-thalassemia. [California Institute for Regenerative Medicine] Press Release

Cell Therapy Catapult to Work with GlaxoSmithKline on Cell Therapies
The Cell Therapy Catapult will be working with GlaxoSmithKline plc to explore potential collaborations in a range of areas relevant to the development of cell therapies, from research projects to technical and regulatory strategy. [Cell Therapy Catapult] Press Release

Enter Our Contest  
Cord Blood News is giving away a free registration for the MSC 2013 – Adult Stem Cell Therapy and Regenerative Medicine in Cleveland! Gain a diverse, global perspective on regenerative medicine and adult stem cell therapy. Click here to enter.

POLICY NEWS

National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

From our sponsor:
Looking for ALDH+ cancer stem cells?
Watch a video to see how ALDEFLUORTM can help.

EVENTS
NEW CIRM/ARM: Reimbursement Strategies for Stem Cell and Regenerative Medicine
June 20, 10:00AM (PT in US)
Webinar

Visit our events page to see a complete list of events in the cord blood community.
JOB OPPORTUNITIES

NEW Postdoctoral Position –  Hematopoiesis Research (Sanquin)

NEW PhD Student Position – Hematopoietic Stem Cells (Katholieke Universiteit Leuven)

Postdoctoral Researcher – Hematopoietic Stem Cells (Albert Einstein College of Medicine)

Assistant Professor – Stem Cell Transplantation (Boston Children’s Hospital/Harvard Medical School)

Postdoctoral Fellow – Stem Cell and Cancer Biology (Johns Hopkins University School of Medicine)

Postdoctoral Position – Novel Gene Discovery (St. Jude Children’s Research Hospital)


Recruit Top Talent: Reach more than 50,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Cord Blood News: Archives | Events | Contact Us